Clinical trial · Interventional
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
NCT03051581CI-TRIAL-00025947unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, T-Cell, Peripheral | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET/ CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FDG PET/CT-based prognostic model of PTCL
- description
- The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
- interventionNames
- Device: 18F-FDG PET/ CT
Primary outcomes (1)
- measure
- 3 year progression-free survival
- timeFrame
- up to 3 years after initial diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * newly diagnosed PTCL * treated using an anthracycline-containing regimen * minimal follow-up at 6 months after the completion of first-line treatment * complete medical history and clinicopathological data Exclusion Criteria: * secondary malignant disease * serious infection or inflammation (e.g., HIV) * primary central nervous system lymphoma * hepatic or renal dysfunction.
References
Publications (0)
Data not yet available
No reference posted for this study.